Literature DB >> 25738671

Clinical management of potential bioterrorism-related conditions.

Amesh A Adalja, Eric Toner, Thomas V Inglesby.   

Abstract

The agents most likely to be used in bioterrorism attacks are reviewed, along with the clinical syndromes they produce and their treatment.

Mesh：

Year:  2015        PMID： 25738671     DOI： 10.1056/NEJMra1409755

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


  20 in total

Review 1.  Neuroterrorism Preparedness for the Neurohospitalist.

Authors:  Maj Samuel A Ralston; Maj Brian P Murray; Daniel Vela-Duarte; Karen D Orjuela; Daniel M Pastula
Journal:  Neurohospitalist       Date:  2018-10-21

2.  Tularemia vaccine: Safety, reactogenicity, "Take" skin reactions, and antibody responses following vaccination with a new lot of the Francisella tularensis live vaccine strain - A phase 2 randomized clinical Trial.

Authors:  Mark J Mulligan; Jack T Stapleton; Wendy A Keitel; Sharon E Frey; Wilbur H Chen; Nadine Rouphael; Srilatha Edupuganti; Allison Beck; Patricia L Winokur; Hana M El Sahly; Shital M Patel; Robert L Atmar; Irene Graham; Edwin Anderson; Samer S El-Kamary; Marcela F Pasetti; Marcelo B Sztein; Heather Hill; Johannes B Goll
Journal:  Vaccine       Date:  2017-07-24       Impact factor: 3.641

3.  Parenteral Administration of Capsule Depolymerase EnvD Prevents Lethal Inhalation Anthrax Infection.

Authors:  David Negus; Julia Vipond; Graham J Hatch; Emma L Rayner; Peter W Taylor
Journal:  Antimicrob Agents Chemother       Date:  2015-10-05       Impact factor: 5.191

4.  The Fluorocycline TP-271 Is Efficacious in Models of Aerosolized Bacillus anthracis Infection in BALB/c Mice and Cynomolgus Macaques.

Authors:  Trudy H Grossman; Michael S Anderson; Lindsay Drabek; Melanie Gooldy; Henry S Heine; Lisa N Henning; Winston Lin; Joseph V Newman; Rene Nevarez; Kaylyn Siefkas-Patterson; Anne K Radcliff; Joyce A Sutcliffe
Journal:  Antimicrob Agents Chemother       Date:  2017-09-22       Impact factor: 5.191

5.  In Vitro and In Vivo Characterization of Tebipenem (TBP), an Orally Active Carbapenem, against Biothreat Pathogens.

Authors:  Nicholas P Clayton; Akash Jain; Stephanie A Halasohoris; Lisa M Pysz; Sanae Lembirik; Steven D Zumbrun; Christopher D Kane; Michael J Hackett; Denise Pfefferle; M Autumn Smiley; Michael S Anderson; Henry Heine; Gabriel T Meister; Michael J Pucci
Journal:  Antimicrob Agents Chemother       Date:  2021-02-16       Impact factor: 5.191

6.  Bacillus anthracis Edema Toxin Increases Fractional Free Water and Sodium Reabsorption in an Isolated Perfused Rat Kidney Model.

Authors:  Dharmvir S Jaswal; Xizhong Cui; Parizad Torabi-Parizi; Lernik Ohanjanian; Hannish Sampath-Kumar; Yvonne Fitz; Yan Li; Wanying Xu; Peter Q Eichacker
Journal:  Infect Immun       Date:  2017-06-20       Impact factor: 3.441

7.  Bacillus anthracis edema toxin inhibits hypoxic pulmonary vasoconstriction via edema factor and cAMP-mediated mechanisms in isolated perfused rat lungs.

Authors:  Xizhong Cui; Jeffrey Wang; Yan Li; Zoe G Couse; Thomas F Risoleo; Mahtab Moayeri; Stephen H Leppla; Daniela Malide; Zu-Xi Yu; Peter Q Eichacker
Journal:  Am J Physiol Heart Circ Physiol       Date:  2020-10-16       Impact factor: 4.733

8.  Evaluation of the European Committee on Antimicrobial Susceptibility Testing Guidelines for Rapid Antimicrobial Susceptibility Testing of Bacillus anthracis-, Yersinia pestis- and Francisella tularensis-Positive Blood Cultures.

Authors:  Ohad Shifman; Tamar Aminov; Moshe Aftalion; David Gur; Hila Cohen; Elad Bar-David; Ofer Cohen; Emanuelle Mamroud; Haim Levy; Ronit Aloni-Grinstein; Ida Steinberger-Levy; Shahar Rotem
Journal:  Microorganisms       Date:  2021-05-13

9.  Safety, Tolerability, and Pharmacokinetics of NTM-1632, a Novel Mixture of Three Monoclonal Antibodies against Botulinum Toxin B.

Authors:  J T Guptill; S M Raja; V C Juel; E B Walter; M Cohen-Wolkowiez; H Hill; E Sendra; B Hauser; P Jackson; G K Swamy
Journal:  Antimicrob Agents Chemother       Date:  2021-06-17       Impact factor: 5.191

10.  Immunological Characterization and Neutralizing Ability of Monoclonal Antibodies Directed Against Botulinum Neurotoxin Type H.

Authors:  Yongfeng Fan; Jason R Barash; Jianlong Lou; Fraser Conrad; James D Marks; Stephen S Arnon
Journal:  J Infect Dis       Date:  2016-03-01       Impact factor: 5.226
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.